Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation
Traumatic brain injury (TBI) induces secondary biochemical changes that contribute to delayed neuroinflammation, neuronal cell death, and neurological dysfunction. Attenuating such secondary injury has provided the conceptual basis for neuroprotective treatments. Despite strong experimental data, m...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/15/1/1216 |
id |
doaj-a225b2c7a82248cc8e220a167e752f74 |
---|---|
record_format |
Article |
spelling |
doaj-a225b2c7a82248cc8e220a167e752f742020-11-24T21:50:01ZengMDPI AGInternational Journal of Molecular Sciences1422-00672014-01-011511216123610.3390/ijms15011216ijms15011216Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical TranslationShruti V. Kabadi0Alan I. Faden1Department of Anesthesiology, Center for Shock, Trauma and Anesthesiology Research (STAR), National Study Center for Trauma and EMS, University of Maryland School of Medicine, Baltimore, MD 21201, USADepartment of Anesthesiology, Center for Shock, Trauma and Anesthesiology Research (STAR), National Study Center for Trauma and EMS, University of Maryland School of Medicine, Baltimore, MD 21201, USATraumatic brain injury (TBI) induces secondary biochemical changes that contribute to delayed neuroinflammation, neuronal cell death, and neurological dysfunction. Attenuating such secondary injury has provided the conceptual basis for neuroprotective treatments. Despite strong experimental data, more than 30 clinical trials of neuroprotection in TBI patients have failed. In part, these failures likely reflect methodological differences between the clinical and animal studies, as well as inadequate pre-clinical evaluation and/or trial design problems. However, recent changes in experimental approach and advances in clinical trial methodology have raised the potential for successful clinical translation. Here we critically analyze the current limitations and translational opportunities for developing successful neuroprotective therapies for TBI.http://www.mdpi.com/1422-0067/15/1/1216experimental head injury clinical trial design translational challenges multipotential neuroprotective approachesprogrammed cell death caspase-dependent and AIF-mediated cell death microglial and astrocyte activation autophagy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shruti V. Kabadi Alan I. Faden |
spellingShingle |
Shruti V. Kabadi Alan I. Faden Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation International Journal of Molecular Sciences experimental head injury clinical trial design translational challenges multipotential neuroprotective approaches programmed cell death caspase-dependent and AIF-mediated cell death microglial and astrocyte activation autophagy |
author_facet |
Shruti V. Kabadi Alan I. Faden |
author_sort |
Shruti V. Kabadi |
title |
Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation |
title_short |
Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation |
title_full |
Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation |
title_fullStr |
Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation |
title_full_unstemmed |
Neuroprotective Strategies for Traumatic Brain Injury: Improving Clinical Translation |
title_sort |
neuroprotective strategies for traumatic brain injury: improving clinical translation |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2014-01-01 |
description |
Traumatic brain injury (TBI) induces secondary biochemical changes that contribute to delayed neuroinflammation, neuronal cell death, and neurological dysfunction. Attenuating such secondary injury has provided the conceptual basis for neuroprotective treatments. Despite strong experimental data, more than 30 clinical trials of neuroprotection in TBI patients have failed. In part, these failures likely reflect methodological differences between the clinical and animal studies, as well as inadequate pre-clinical evaluation and/or trial design problems. However, recent changes in experimental approach and advances in clinical trial methodology have raised the potential for successful clinical translation. Here we critically analyze the current limitations and translational opportunities for developing successful neuroprotective therapies for TBI. |
topic |
experimental head injury clinical trial design translational challenges multipotential neuroprotective approaches programmed cell death caspase-dependent and AIF-mediated cell death microglial and astrocyte activation autophagy |
url |
http://www.mdpi.com/1422-0067/15/1/1216 |
work_keys_str_mv |
AT shrutivkabadi neuroprotectivestrategiesfortraumaticbraininjuryimprovingclinicaltranslation AT alanifaden neuroprotectivestrategiesfortraumaticbraininjuryimprovingclinicaltranslation |
_version_ |
1725885849441140736 |